Thursday, September 24, 2020
Asked about obstacles that make them second-guess outsourcing work to bioanalytical contract research (CROs), pharmaceutical companies do not mince words: “regulatory compliance and scientific expertise,” and “unresponsiveness and imprecise data”1 ...